Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?

BACKGROUND. The role of continued trastuzumab after progression in women with human epidermal growth factor receptor (HER)-2(+) metastatic breast cancer is controversial. Controlled clinical trials that establish a benefit from continued trastuzumab have been difficult to complete. METHODS. In the N...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wong, Yu-Ning, Ottesen, Rebecca A., Hughes, Melissa E., Niland, Joyce C., Theriault, Richard, Edge, Stephen B., Blayney, Douglas, Weeks, Jane C.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2011
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228199/
https://ncbi.nlm.nih.gov/pubmed/21450786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0360
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky